Cambridge, Mass. – November 06, 2026 -- CREATE Medicines, Inc. says it has treated more than 80 patients with in vivo CAR therapy, which it describes as the largest clinical dataset in the field. The company is now taking its four clinical-stage programs to investors and prospective partners at the Jefferies Global Healthcare Conference in London.
CREATE schedules one-on-one meetings at Jefferies London on Nov. 16-19, 2026
Management will hold one-on-one meetings at the Waldorf Hilton and ME London during the conference, which runs from Nov. 16 to 19, 2026. CEO and Co-Founder Daniel Getts, PhD, and Chief Medical Officer Matthew Maurer, MD, will represent the clinical-stage biotech.
Investors must request meetings through their Jefferies representative. Prospective partners can contact the company's business development team directly.
Four in vivo CAR candidates target CD19, GPC3, TROP2 and HER2 across autoimmune disease and oncology
The pipeline comprises four clinical-stage programs, each aimed at a different antigen:
- CRT-402: CD19-targeted in vivo CAR
- MT-303: GPC3-targeted in vivo CAR
- MT-302: TROP2-targeted in vivo CAR
- MT-304: HER2-targeted in vivo CAR
RNA-based platform programs immune cells inside the body for transient or stable CAR expression
CREATE's proprietary platform selectively programs immune cells directly in the body, all from RNA. It can produce either transient or stable CAR expression. The company says its mRNA-LNP technology is designed to deliver scalable, repeat-dose, off-the-shelf immunotherapies.